EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG NVS resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders.

On June 25, 2020, the Company agreed to pay $225 million in criminal fines and disgorge $112 million in settling bribery allegations brought forth by the U.S. Department of Justice and the Securities and Exchange Commission. Novartis was under investigation for claims that: (1) the Company had bribed doctors and hospitals in Greece to prescribe "Novartis-branded pharmaceuticals"; (2) the Company had paid bribes in Vietnam to advance their business; and (3) the Company had falsified their financial records to conceal said activities. On this news, the Company's share prices dropped by $2.50 over the following trading session.

Rosen Law Firm is preparing a securities lawsuit on behalf of Novartis shareholders. If you purchased securities of Novartis please visit the firm's website at http://www.rosenlegal.com/cases-register-1887.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.